GCTK vs. XAIR, INBS, DHAI, MHUA, BTCY, WOK, LYRA, PAVM, CODX, and SSKN
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Beyond Air (XAIR), Intelligent Bio Solutions (INBS), DIH Holding US (DHAI), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), WORK Medical Technology Group (WOK), Lyra Therapeutics (LYRA), PAVmed (PAVM), Co-Diagnostics (CODX), and Strata Skin Sciences (SSKN). These companies are all part of the "medical equipment" industry.
GlucoTrack vs. Its Competitors
Beyond Air (NASDAQ:XAIR) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.
31.5% of Beyond Air shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 19.4% of Beyond Air shares are owned by insiders. Comparatively, 12.9% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
GlucoTrack has a net margin of 0.00% compared to Beyond Air's net margin of -1,258.46%. GlucoTrack's return on equity of 0.00% beat Beyond Air's return on equity.
In the previous week, Beyond Air had 7 more articles in the media than GlucoTrack. MarketBeat recorded 9 mentions for Beyond Air and 2 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.80 beat Beyond Air's score of 0.40 indicating that GlucoTrack is being referred to more favorably in the news media.
GlucoTrack has lower revenue, but higher earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
Beyond Air currently has a consensus price target of $23.67, indicating a potential upside of 612.85%. Given Beyond Air's stronger consensus rating and higher possible upside, equities analysts clearly believe Beyond Air is more favorable than GlucoTrack.
Beyond Air has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, GlucoTrack has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500.
Summary
Beyond Air beats GlucoTrack on 11 of the 16 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
This page (NASDAQ:GCTK) was last updated on 7/24/2025 by MarketBeat.com Staff
